nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLCO1B1—Conjugated Estrogens—osteoporosis	0.078	0.161	CbGbCtD
Sirolimus—SLCO1B1—Estradiol—osteoporosis	0.0685	0.141	CbGbCtD
Sirolimus—CYP3A7—Estradiol—osteoporosis	0.0402	0.0828	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0402	0.0828	CbGbCtD
Sirolimus—ABCB1—Ethinyl Estradiol—osteoporosis	0.0304	0.0627	CbGbCtD
Sirolimus—CYP3A5—Estradiol—osteoporosis	0.0301	0.0621	CbGbCtD
Sirolimus—CYP3A4—Estropipate—osteoporosis	0.0283	0.0583	CbGbCtD
Sirolimus—CYP3A4—Calcitriol—osteoporosis	0.0283	0.0583	CbGbCtD
Sirolimus—CYP3A4—Ergocalciferol—osteoporosis	0.0226	0.0466	CbGbCtD
Sirolimus—ABCB1—Conjugated Estrogens—osteoporosis	0.0223	0.046	CbGbCtD
Sirolimus—ABCB1—Estradiol—osteoporosis	0.0196	0.0404	CbGbCtD
Sirolimus—CYP3A4—Raloxifene—osteoporosis	0.0189	0.0389	CbGbCtD
Sirolimus—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0182	0.0376	CbGbCtD
Sirolimus—CYP3A4—Cholecalciferol—osteoporosis	0.0146	0.03	CbGbCtD
Sirolimus—CYP3A4—Conjugated Estrogens—osteoporosis	0.0134	0.0276	CbGbCtD
Sirolimus—CYP3A4—Estradiol—osteoporosis	0.0118	0.0242	CbGbCtD
Sirolimus—Anorexia—Pamidronate—osteoporosis	0.000138	0.00042	CcSEcCtD
Sirolimus—Chest pain—Zoledronate—osteoporosis	0.000138	0.00042	CcSEcCtD
Sirolimus—Arthralgia—Zoledronate—osteoporosis	0.000138	0.00042	CcSEcCtD
Sirolimus—Myalgia—Zoledronate—osteoporosis	0.000138	0.00042	CcSEcCtD
Sirolimus—Palpitations—Conjugated Estrogens—osteoporosis	0.000138	0.00042	CcSEcCtD
Sirolimus—Insomnia—Risedronate—osteoporosis	0.000138	0.000419	CcSEcCtD
Sirolimus—Anxiety—Zoledronate—osteoporosis	0.000138	0.000418	CcSEcCtD
Sirolimus—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000138	0.000417	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000137	0.000417	CcSEcCtD
Sirolimus—Paraesthesia—Risedronate—osteoporosis	0.000137	0.000416	CcSEcCtD
Sirolimus—Pruritus—Estropipate—osteoporosis	0.000137	0.000415	CcSEcCtD
Sirolimus—Discomfort—Zoledronate—osteoporosis	0.000137	0.000415	CcSEcCtD
Sirolimus—Asthenia—Alendronate—osteoporosis	0.000137	0.000415	CcSEcCtD
Sirolimus—Hypersensitivity—Ibandronate—osteoporosis	0.000137	0.000414	CcSEcCtD
Sirolimus—Cough—Conjugated Estrogens—osteoporosis	0.000137	0.000414	CcSEcCtD
Sirolimus—Dyspnoea—Risedronate—osteoporosis	0.000136	0.000413	CcSEcCtD
Sirolimus—Hypotension—Pamidronate—osteoporosis	0.000136	0.000412	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000135	0.00041	CcSEcCtD
Sirolimus—Pruritus—Alendronate—osteoporosis	0.000135	0.000409	CcSEcCtD
Sirolimus—Dyspepsia—Risedronate—osteoporosis	0.000135	0.000408	CcSEcCtD
Sirolimus—Tinnitus—Estradiol—osteoporosis	0.000134	0.000407	CcSEcCtD
Sirolimus—Constipation—Ethinyl Estradiol—osteoporosis	0.000134	0.000407	CcSEcCtD
Sirolimus—Confusional state—Zoledronate—osteoporosis	0.000134	0.000406	CcSEcCtD
Sirolimus—Hypersensitivity—Calcitriol—osteoporosis	0.000134	0.000406	CcSEcCtD
Sirolimus—Cardiac disorder—Estradiol—osteoporosis	0.000134	0.000405	CcSEcCtD
Sirolimus—Chest pain—Conjugated Estrogens—osteoporosis	0.000133	0.000404	CcSEcCtD
Sirolimus—Arthralgia—Conjugated Estrogens—osteoporosis	0.000133	0.000404	CcSEcCtD
Sirolimus—Myalgia—Conjugated Estrogens—osteoporosis	0.000133	0.000404	CcSEcCtD
Sirolimus—Asthenia—Ibandronate—osteoporosis	0.000133	0.000404	CcSEcCtD
Sirolimus—Anxiety—Conjugated Estrogens—osteoporosis	0.000133	0.000403	CcSEcCtD
Sirolimus—Nausea—Etidronic acid—osteoporosis	0.000133	0.000403	CcSEcCtD
Sirolimus—Oedema—Zoledronate—osteoporosis	0.000133	0.000403	CcSEcCtD
Sirolimus—Anaphylactic shock—Zoledronate—osteoporosis	0.000133	0.000403	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000132	0.000402	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000132	0.000401	CcSEcCtD
Sirolimus—Diarrhoea—Estropipate—osteoporosis	0.000132	0.000401	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Risedronate—osteoporosis	0.000132	0.0004	CcSEcCtD
Sirolimus—Infection—Zoledronate—osteoporosis	0.000132	0.0004	CcSEcCtD
Sirolimus—Insomnia—Pamidronate—osteoporosis	0.000131	0.000399	CcSEcCtD
Sirolimus—Pruritus—Ibandronate—osteoporosis	0.000131	0.000398	CcSEcCtD
Sirolimus—Pain—Risedronate—osteoporosis	0.000131	0.000396	CcSEcCtD
Sirolimus—Constipation—Risedronate—osteoporosis	0.000131	0.000396	CcSEcCtD
Sirolimus—Angiopathy—Estradiol—osteoporosis	0.000131	0.000396	CcSEcCtD
Sirolimus—Shock—Zoledronate—osteoporosis	0.000131	0.000396	CcSEcCtD
Sirolimus—Paraesthesia—Pamidronate—osteoporosis	0.00013	0.000396	CcSEcCtD
Sirolimus—Diarrhoea—Alendronate—osteoporosis	0.00013	0.000395	CcSEcCtD
Sirolimus—Asthenia—Calcitriol—osteoporosis	0.00013	0.000395	CcSEcCtD
Sirolimus—Nervous system disorder—Zoledronate—osteoporosis	0.00013	0.000395	CcSEcCtD
Sirolimus—Immune system disorder—Estradiol—osteoporosis	0.00013	0.000394	CcSEcCtD
Sirolimus—Thrombocytopenia—Zoledronate—osteoporosis	0.00013	0.000394	CcSEcCtD
Sirolimus—Mediastinal disorder—Estradiol—osteoporosis	0.00013	0.000394	CcSEcCtD
Sirolimus—Dyspnoea—Pamidronate—osteoporosis	0.00013	0.000393	CcSEcCtD
Sirolimus—Tachycardia—Zoledronate—osteoporosis	0.00013	0.000393	CcSEcCtD
Sirolimus—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000129	0.000392	CcSEcCtD
Sirolimus—Chills—Estradiol—osteoporosis	0.000129	0.000392	CcSEcCtD
Sirolimus—Somnolence—Pamidronate—osteoporosis	0.000129	0.000392	CcSEcCtD
Sirolimus—Skin disorder—Zoledronate—osteoporosis	0.000129	0.000391	CcSEcCtD
Sirolimus—Pruritus—Calcitriol—osteoporosis	0.000128	0.00039	CcSEcCtD
Sirolimus—Hyperhidrosis—Zoledronate—osteoporosis	0.000128	0.000389	CcSEcCtD
Sirolimus—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000128	0.000389	CcSEcCtD
Sirolimus—Diarrhoea—Raloxifene—osteoporosis	0.000128	0.000389	CcSEcCtD
Sirolimus—Dyspepsia—Pamidronate—osteoporosis	0.000128	0.000388	CcSEcCtD
Sirolimus—Dizziness—Estropipate—osteoporosis	0.000128	0.000388	CcSEcCtD
Sirolimus—Oedema—Conjugated Estrogens—osteoporosis	0.000128	0.000388	CcSEcCtD
Sirolimus—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000128	0.000388	CcSEcCtD
Sirolimus—Infection—Conjugated Estrogens—osteoporosis	0.000127	0.000385	CcSEcCtD
Sirolimus—Diarrhoea—Ibandronate—osteoporosis	0.000127	0.000385	CcSEcCtD
Sirolimus—Anorexia—Zoledronate—osteoporosis	0.000127	0.000384	CcSEcCtD
Sirolimus—Decreased appetite—Pamidronate—osteoporosis	0.000126	0.000383	CcSEcCtD
Sirolimus—Dizziness—Alendronate—osteoporosis	0.000126	0.000382	CcSEcCtD
Sirolimus—Shock—Conjugated Estrogens—osteoporosis	0.000126	0.000381	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000125	0.00038	CcSEcCtD
Sirolimus—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000125	0.00038	CcSEcCtD
Sirolimus—Malnutrition—Estradiol—osteoporosis	0.000125	0.00038	CcSEcCtD
Sirolimus—Gastrointestinal pain—Risedronate—osteoporosis	0.000125	0.000379	CcSEcCtD
Sirolimus—Tachycardia—Conjugated Estrogens—osteoporosis	0.000125	0.000378	CcSEcCtD
Sirolimus—Constipation—Pamidronate—osteoporosis	0.000124	0.000377	CcSEcCtD
Sirolimus—Pain—Pamidronate—osteoporosis	0.000124	0.000377	CcSEcCtD
Sirolimus—Diarrhoea—Calcitriol—osteoporosis	0.000124	0.000377	CcSEcCtD
Sirolimus—Skin disorder—Conjugated Estrogens—osteoporosis	0.000124	0.000376	CcSEcCtD
Sirolimus—Hypotension—Zoledronate—osteoporosis	0.000124	0.000376	CcSEcCtD
Sirolimus—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000124	0.000376	CcSEcCtD
Sirolimus—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000124	0.000376	CcSEcCtD
Sirolimus—Dizziness—Raloxifene—osteoporosis	0.000124	0.000376	CcSEcCtD
Sirolimus—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000124	0.000375	CcSEcCtD
Sirolimus—Flatulence—Estradiol—osteoporosis	0.000123	0.000375	CcSEcCtD
Sirolimus—Tension—Estradiol—osteoporosis	0.000123	0.000373	CcSEcCtD
Sirolimus—Vomiting—Estropipate—osteoporosis	0.000123	0.000373	CcSEcCtD
Sirolimus—Dizziness—Ibandronate—osteoporosis	0.000123	0.000372	CcSEcCtD
Sirolimus—Rash—Estropipate—osteoporosis	0.000122	0.00037	CcSEcCtD
Sirolimus—Dermatitis—Estropipate—osteoporosis	0.000122	0.00037	CcSEcCtD
Sirolimus—Anorexia—Conjugated Estrogens—osteoporosis	0.000122	0.000369	CcSEcCtD
Sirolimus—Nervousness—Estradiol—osteoporosis	0.000122	0.000369	CcSEcCtD
Sirolimus—Back pain—Estradiol—osteoporosis	0.000121	0.000368	CcSEcCtD
Sirolimus—Headache—Estropipate—osteoporosis	0.000121	0.000367	CcSEcCtD
Sirolimus—Vomiting—Alendronate—osteoporosis	0.000121	0.000367	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000121	0.000367	CcSEcCtD
Sirolimus—Abdominal pain—Risedronate—osteoporosis	0.000121	0.000366	CcSEcCtD
Sirolimus—Body temperature increased—Risedronate—osteoporosis	0.000121	0.000366	CcSEcCtD
Sirolimus—Muscle spasms—Estradiol—osteoporosis	0.00012	0.000365	CcSEcCtD
Sirolimus—Rash—Alendronate—osteoporosis	0.00012	0.000364	CcSEcCtD
Sirolimus—Insomnia—Zoledronate—osteoporosis	0.00012	0.000364	CcSEcCtD
Sirolimus—Dermatitis—Alendronate—osteoporosis	0.00012	0.000364	CcSEcCtD
Sirolimus—Feeling abnormal—Pamidronate—osteoporosis	0.00012	0.000363	CcSEcCtD
Sirolimus—Hypotension—Conjugated Estrogens—osteoporosis	0.000119	0.000362	CcSEcCtD
Sirolimus—Headache—Alendronate—osteoporosis	0.000119	0.000362	CcSEcCtD
Sirolimus—Paraesthesia—Zoledronate—osteoporosis	0.000119	0.000361	CcSEcCtD
Sirolimus—Vomiting—Raloxifene—osteoporosis	0.000119	0.000361	CcSEcCtD
Sirolimus—Gastrointestinal pain—Pamidronate—osteoporosis	0.000119	0.00036	CcSEcCtD
Sirolimus—Dyspnoea—Zoledronate—osteoporosis	0.000118	0.000359	CcSEcCtD
Sirolimus—Rash—Raloxifene—osteoporosis	0.000118	0.000358	CcSEcCtD
Sirolimus—Dermatitis—Raloxifene—osteoporosis	0.000118	0.000358	CcSEcCtD
Sirolimus—Somnolence—Zoledronate—osteoporosis	0.000118	0.000358	CcSEcCtD
Sirolimus—Vomiting—Ibandronate—osteoporosis	0.000118	0.000358	CcSEcCtD
Sirolimus—Tremor—Estradiol—osteoporosis	0.000117	0.000356	CcSEcCtD
Sirolimus—Headache—Raloxifene—osteoporosis	0.000117	0.000356	CcSEcCtD
Sirolimus—Rash—Ibandronate—osteoporosis	0.000117	0.000355	CcSEcCtD
Sirolimus—Dermatitis—Ibandronate—osteoporosis	0.000117	0.000354	CcSEcCtD
Sirolimus—Dyspepsia—Zoledronate—osteoporosis	0.000117	0.000354	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000116	0.000353	CcSEcCtD
Sirolimus—Ill-defined disorder—Estradiol—osteoporosis	0.000116	0.000353	CcSEcCtD
Sirolimus—Headache—Ibandronate—osteoporosis	0.000116	0.000352	CcSEcCtD
Sirolimus—Insomnia—Conjugated Estrogens—osteoporosis	0.000116	0.000351	CcSEcCtD
Sirolimus—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000115	0.00035	CcSEcCtD
Sirolimus—Vomiting—Calcitriol—osteoporosis	0.000115	0.00035	CcSEcCtD
Sirolimus—Decreased appetite—Zoledronate—osteoporosis	0.000115	0.00035	CcSEcCtD
Sirolimus—Agitation—Estradiol—osteoporosis	0.000115	0.000349	CcSEcCtD
Sirolimus—Nausea—Estropipate—osteoporosis	0.000115	0.000348	CcSEcCtD
Sirolimus—Abdominal pain—Pamidronate—osteoporosis	0.000115	0.000348	CcSEcCtD
Sirolimus—Body temperature increased—Pamidronate—osteoporosis	0.000115	0.000348	CcSEcCtD
Sirolimus—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000115	0.000348	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000115	0.000348	CcSEcCtD
Sirolimus—Angioedema—Estradiol—osteoporosis	0.000115	0.000347	CcSEcCtD
Sirolimus—Rash—Calcitriol—osteoporosis	0.000114	0.000347	CcSEcCtD
Sirolimus—Dermatitis—Calcitriol—osteoporosis	0.000114	0.000347	CcSEcCtD
Sirolimus—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000114	0.000346	CcSEcCtD
Sirolimus—Headache—Calcitriol—osteoporosis	0.000114	0.000345	CcSEcCtD
Sirolimus—Somnolence—Conjugated Estrogens—osteoporosis	0.000114	0.000345	CcSEcCtD
Sirolimus—Pain—Zoledronate—osteoporosis	0.000113	0.000344	CcSEcCtD
Sirolimus—Constipation—Zoledronate—osteoporosis	0.000113	0.000344	CcSEcCtD
Sirolimus—Nausea—Alendronate—osteoporosis	0.000113	0.000343	CcSEcCtD
Sirolimus—Malaise—Estradiol—osteoporosis	0.000113	0.000343	CcSEcCtD
Sirolimus—Hypersensitivity—Risedronate—osteoporosis	0.000113	0.000342	CcSEcCtD
Sirolimus—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000112	0.000341	CcSEcCtD
Sirolimus—Asthenia—Ethinyl Estradiol—osteoporosis	0.000112	0.000341	CcSEcCtD
Sirolimus—Syncope—Estradiol—osteoporosis	0.000112	0.000341	CcSEcCtD
Sirolimus—Nausea—Raloxifene—osteoporosis	0.000111	0.000338	CcSEcCtD
Sirolimus—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000111	0.000337	CcSEcCtD
Sirolimus—Pruritus—Ethinyl Estradiol—osteoporosis	0.000111	0.000336	CcSEcCtD
Sirolimus—Palpitations—Estradiol—osteoporosis	0.000111	0.000336	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00011	0.000335	CcSEcCtD
Sirolimus—Nausea—Ibandronate—osteoporosis	0.00011	0.000334	CcSEcCtD
Sirolimus—Loss of consciousness—Estradiol—osteoporosis	0.00011	0.000334	CcSEcCtD
Sirolimus—Asthenia—Risedronate—osteoporosis	0.00011	0.000333	CcSEcCtD
Sirolimus—Feeling abnormal—Zoledronate—osteoporosis	0.000109	0.000332	CcSEcCtD
Sirolimus—Cough—Estradiol—osteoporosis	0.000109	0.000332	CcSEcCtD
Sirolimus—Pain—Conjugated Estrogens—osteoporosis	0.000109	0.000331	CcSEcCtD
Sirolimus—Constipation—Conjugated Estrogens—osteoporosis	0.000109	0.000331	CcSEcCtD
Sirolimus—Gastrointestinal pain—Zoledronate—osteoporosis	0.000109	0.000329	CcSEcCtD
Sirolimus—Hypertension—Estradiol—osteoporosis	0.000108	0.000328	CcSEcCtD
Sirolimus—Pruritus—Risedronate—osteoporosis	0.000108	0.000328	CcSEcCtD
Sirolimus—Nausea—Calcitriol—osteoporosis	0.000108	0.000327	CcSEcCtD
Sirolimus—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000107	0.000325	CcSEcCtD
Sirolimus—Hypersensitivity—Pamidronate—osteoporosis	0.000107	0.000325	CcSEcCtD
Sirolimus—Arthralgia—Estradiol—osteoporosis	0.000107	0.000324	CcSEcCtD
Sirolimus—Chest pain—Estradiol—osteoporosis	0.000107	0.000324	CcSEcCtD
Sirolimus—Myalgia—Estradiol—osteoporosis	0.000107	0.000324	CcSEcCtD
Sirolimus—Anxiety—Estradiol—osteoporosis	0.000106	0.000322	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000106	0.000321	CcSEcCtD
Sirolimus—Discomfort—Estradiol—osteoporosis	0.000105	0.00032	CcSEcCtD
Sirolimus—Abdominal pain—Zoledronate—osteoporosis	0.000105	0.000318	CcSEcCtD
Sirolimus—Body temperature increased—Zoledronate—osteoporosis	0.000105	0.000318	CcSEcCtD
Sirolimus—Diarrhoea—Risedronate—osteoporosis	0.000105	0.000317	CcSEcCtD
Sirolimus—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000104	0.000317	CcSEcCtD
Sirolimus—Asthenia—Pamidronate—osteoporosis	0.000104	0.000316	CcSEcCtD
Sirolimus—Dizziness—Ethinyl Estradiol—osteoporosis	0.000104	0.000314	CcSEcCtD
Sirolimus—Confusional state—Estradiol—osteoporosis	0.000103	0.000313	CcSEcCtD
Sirolimus—Pruritus—Pamidronate—osteoporosis	0.000103	0.000312	CcSEcCtD
Sirolimus—Anaphylactic shock—Estradiol—osteoporosis	0.000102	0.00031	CcSEcCtD
Sirolimus—Oedema—Estradiol—osteoporosis	0.000102	0.00031	CcSEcCtD
Sirolimus—Infection—Estradiol—osteoporosis	0.000102	0.000308	CcSEcCtD
Sirolimus—Dizziness—Risedronate—osteoporosis	0.000101	0.000307	CcSEcCtD
Sirolimus—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000101	0.000306	CcSEcCtD
Sirolimus—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000101	0.000306	CcSEcCtD
Sirolimus—Shock—Estradiol—osteoporosis	0.000101	0.000305	CcSEcCtD
Sirolimus—Nervous system disorder—Estradiol—osteoporosis	0.0001	0.000304	CcSEcCtD
Sirolimus—Tachycardia—Estradiol—osteoporosis	9.98e-05	0.000303	CcSEcCtD
Sirolimus—Vomiting—Ethinyl Estradiol—osteoporosis	9.97e-05	0.000302	CcSEcCtD
Sirolimus—Diarrhoea—Pamidronate—osteoporosis	9.94e-05	0.000302	CcSEcCtD
Sirolimus—Skin disorder—Estradiol—osteoporosis	9.93e-05	0.000301	CcSEcCtD
Sirolimus—Hyperhidrosis—Estradiol—osteoporosis	9.89e-05	0.0003	CcSEcCtD
Sirolimus—Rash—Ethinyl Estradiol—osteoporosis	9.88e-05	0.0003	CcSEcCtD
Sirolimus—Dermatitis—Ethinyl Estradiol—osteoporosis	9.87e-05	0.0003	CcSEcCtD
Sirolimus—Headache—Ethinyl Estradiol—osteoporosis	9.82e-05	0.000298	CcSEcCtD
Sirolimus—Hypersensitivity—Zoledronate—osteoporosis	9.78e-05	0.000297	CcSEcCtD
Sirolimus—Vomiting—Risedronate—osteoporosis	9.72e-05	0.000295	CcSEcCtD
Sirolimus—Rash—Risedronate—osteoporosis	9.64e-05	0.000292	CcSEcCtD
Sirolimus—Dermatitis—Risedronate—osteoporosis	9.63e-05	0.000292	CcSEcCtD
Sirolimus—Dizziness—Pamidronate—osteoporosis	9.61e-05	0.000291	CcSEcCtD
Sirolimus—Headache—Risedronate—osteoporosis	9.57e-05	0.00029	CcSEcCtD
Sirolimus—Asthenia—Zoledronate—osteoporosis	9.52e-05	0.000289	CcSEcCtD
Sirolimus—Hypersensitivity—Conjugated Estrogens—osteoporosis	9.42e-05	0.000286	CcSEcCtD
Sirolimus—Pruritus—Zoledronate—osteoporosis	9.39e-05	0.000285	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Estradiol—osteoporosis	9.32e-05	0.000283	CcSEcCtD
Sirolimus—Nausea—Ethinyl Estradiol—osteoporosis	9.31e-05	0.000282	CcSEcCtD
Sirolimus—Insomnia—Estradiol—osteoporosis	9.25e-05	0.000281	CcSEcCtD
Sirolimus—Vomiting—Pamidronate—osteoporosis	9.24e-05	0.00028	CcSEcCtD
Sirolimus—Paraesthesia—Estradiol—osteoporosis	9.18e-05	0.000279	CcSEcCtD
Sirolimus—Asthenia—Conjugated Estrogens—osteoporosis	9.17e-05	0.000278	CcSEcCtD
Sirolimus—Rash—Pamidronate—osteoporosis	9.16e-05	0.000278	CcSEcCtD
Sirolimus—Dermatitis—Pamidronate—osteoporosis	9.15e-05	0.000278	CcSEcCtD
Sirolimus—Dyspnoea—Estradiol—osteoporosis	9.12e-05	0.000277	CcSEcCtD
Sirolimus—Headache—Pamidronate—osteoporosis	9.1e-05	0.000276	CcSEcCtD
Sirolimus—Somnolence—Estradiol—osteoporosis	9.09e-05	0.000276	CcSEcCtD
Sirolimus—Diarrhoea—Zoledronate—osteoporosis	9.08e-05	0.000275	CcSEcCtD
Sirolimus—Nausea—Risedronate—osteoporosis	9.08e-05	0.000275	CcSEcCtD
Sirolimus—Pruritus—Conjugated Estrogens—osteoporosis	9.04e-05	0.000274	CcSEcCtD
Sirolimus—Dyspepsia—Estradiol—osteoporosis	9e-05	0.000273	CcSEcCtD
Sirolimus—Decreased appetite—Estradiol—osteoporosis	8.89e-05	0.00027	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Estradiol—osteoporosis	8.83e-05	0.000268	CcSEcCtD
Sirolimus—Dizziness—Zoledronate—osteoporosis	8.78e-05	0.000266	CcSEcCtD
Sirolimus—Constipation—Estradiol—osteoporosis	8.75e-05	0.000265	CcSEcCtD
Sirolimus—Pain—Estradiol—osteoporosis	8.75e-05	0.000265	CcSEcCtD
Sirolimus—Diarrhoea—Conjugated Estrogens—osteoporosis	8.74e-05	0.000265	CcSEcCtD
Sirolimus—Nausea—Pamidronate—osteoporosis	8.63e-05	0.000262	CcSEcCtD
Sirolimus—Dizziness—Conjugated Estrogens—osteoporosis	8.45e-05	0.000256	CcSEcCtD
Sirolimus—Vomiting—Zoledronate—osteoporosis	8.44e-05	0.000256	CcSEcCtD
Sirolimus—Feeling abnormal—Estradiol—osteoporosis	8.43e-05	0.000256	CcSEcCtD
Sirolimus—Rash—Zoledronate—osteoporosis	8.37e-05	0.000254	CcSEcCtD
Sirolimus—Gastrointestinal pain—Estradiol—osteoporosis	8.36e-05	0.000254	CcSEcCtD
Sirolimus—Dermatitis—Zoledronate—osteoporosis	8.36e-05	0.000254	CcSEcCtD
Sirolimus—Headache—Zoledronate—osteoporosis	8.31e-05	0.000252	CcSEcCtD
Sirolimus—Vomiting—Conjugated Estrogens—osteoporosis	8.13e-05	0.000246	CcSEcCtD
Sirolimus—Abdominal pain—Estradiol—osteoporosis	8.09e-05	0.000245	CcSEcCtD
Sirolimus—Body temperature increased—Estradiol—osteoporosis	8.09e-05	0.000245	CcSEcCtD
Sirolimus—Rash—Conjugated Estrogens—osteoporosis	8.06e-05	0.000244	CcSEcCtD
Sirolimus—Dermatitis—Conjugated Estrogens—osteoporosis	8.05e-05	0.000244	CcSEcCtD
Sirolimus—Headache—Conjugated Estrogens—osteoporosis	8.01e-05	0.000243	CcSEcCtD
Sirolimus—Nausea—Zoledronate—osteoporosis	7.88e-05	0.000239	CcSEcCtD
Sirolimus—Nausea—Conjugated Estrogens—osteoporosis	7.59e-05	0.00023	CcSEcCtD
Sirolimus—Hypersensitivity—Estradiol—osteoporosis	7.54e-05	0.000229	CcSEcCtD
Sirolimus—Asthenia—Estradiol—osteoporosis	7.34e-05	0.000223	CcSEcCtD
Sirolimus—Pruritus—Estradiol—osteoporosis	7.24e-05	0.000219	CcSEcCtD
Sirolimus—Diarrhoea—Estradiol—osteoporosis	7e-05	0.000212	CcSEcCtD
Sirolimus—Dizziness—Estradiol—osteoporosis	6.76e-05	0.000205	CcSEcCtD
Sirolimus—Vomiting—Estradiol—osteoporosis	6.5e-05	0.000197	CcSEcCtD
Sirolimus—Rash—Estradiol—osteoporosis	6.45e-05	0.000196	CcSEcCtD
Sirolimus—Dermatitis—Estradiol—osteoporosis	6.44e-05	0.000195	CcSEcCtD
Sirolimus—Headache—Estradiol—osteoporosis	6.41e-05	0.000194	CcSEcCtD
Sirolimus—Nausea—Estradiol—osteoporosis	6.08e-05	0.000184	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—SPP1—osteoporosis	3.71e-05	0.0002	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—osteoporosis	3.71e-05	0.0002	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—IDH2—osteoporosis	3.7e-05	0.0002	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MTHFR—osteoporosis	3.69e-05	0.0002	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—osteoporosis	3.69e-05	0.000199	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PSMA5—osteoporosis	3.69e-05	0.000199	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PSMA2—osteoporosis	3.69e-05	0.000199	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ACP5—osteoporosis	3.68e-05	0.000199	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IRS2—osteoporosis	3.67e-05	0.000199	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—osteoporosis	3.67e-05	0.000198	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGA—osteoporosis	3.66e-05	0.000198	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.64e-05	0.000197	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TLN1—osteoporosis	3.63e-05	0.000196	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3.59e-05	0.000194	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KL—osteoporosis	3.59e-05	0.000194	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.58e-05	0.000193	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.54e-05	0.000191	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—IRS2—osteoporosis	3.53e-05	0.000191	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—osteoporosis	3.51e-05	0.00019	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IRS2—osteoporosis	3.51e-05	0.00019	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP27A1—osteoporosis	3.48e-05	0.000188	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.47e-05	0.000188	CbGpPWpGaD
Sirolimus—MTOR—Disease—ENO1—osteoporosis	3.46e-05	0.000187	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—osteoporosis	3.45e-05	0.000187	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	3.45e-05	0.000187	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—osteoporosis	3.45e-05	0.000187	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TPI1—osteoporosis	3.42e-05	0.000185	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—osteoporosis	3.42e-05	0.000185	CbGpPWpGaD
Sirolimus—MTOR—Disease—PSMA2—osteoporosis	3.4e-05	0.000184	CbGpPWpGaD
Sirolimus—MTOR—Disease—PSMA5—osteoporosis	3.4e-05	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTHLH—osteoporosis	3.4e-05	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BMP2—osteoporosis	3.4e-05	0.000184	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—osteoporosis	3.39e-05	0.000183	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ACP5—osteoporosis	3.38e-05	0.000183	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—osteoporosis	3.38e-05	0.000183	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IRS2—osteoporosis	3.35e-05	0.000181	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGB—osteoporosis	3.33e-05	0.00018	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AGER—osteoporosis	3.31e-05	0.000179	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PKM—osteoporosis	3.3e-05	0.000179	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FDPS—osteoporosis	3.3e-05	0.000179	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ADCY5—osteoporosis	3.29e-05	0.000178	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—LEP—osteoporosis	3.28e-05	0.000177	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL1B—osteoporosis	3.23e-05	0.000175	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CA2—osteoporosis	3.22e-05	0.000174	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—OXCT1—osteoporosis	3.22e-05	0.000174	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—P4HB—osteoporosis	3.22e-05	0.000174	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PSMA2—osteoporosis	3.21e-05	0.000174	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PSMA5—osteoporosis	3.21e-05	0.000174	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IRS1—osteoporosis	3.21e-05	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Disease—CALCA—osteoporosis	3.17e-05	0.000172	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—osteoporosis	3.17e-05	0.000171	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GAPDH—osteoporosis	3.16e-05	0.000171	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TPI1—osteoporosis	3.14e-05	0.00017	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MGLL—osteoporosis	3.14e-05	0.00017	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ESR1—osteoporosis	3.13e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—P4HB—osteoporosis	3.13e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPD2—osteoporosis	3.13e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PGLS—osteoporosis	3.13e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KL—osteoporosis	3.12e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.1e-05	0.000167	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—RAP1A—osteoporosis	3.08e-05	0.000166	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—IRS1—osteoporosis	3.08e-05	0.000166	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IRS1—osteoporosis	3.07e-05	0.000166	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	3.06e-05	0.000165	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTH—osteoporosis	3.05e-05	0.000165	CbGpPWpGaD
Sirolimus—FGF2—Disease—ADCY5—osteoporosis	3.04e-05	0.000164	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6R—osteoporosis	3.01e-05	0.000163	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CALCA—osteoporosis	2.99e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAP1A—osteoporosis	2.99e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CNR2—osteoporosis	2.97e-05	0.000161	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—P4HB—osteoporosis	2.96e-05	0.00016	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IRS1—osteoporosis	2.93e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFATC1—osteoporosis	2.92e-05	0.000158	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GAPDH—osteoporosis	2.9e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DKK1—osteoporosis	2.9e-05	0.000157	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRS2—osteoporosis	2.88e-05	0.000156	CbGpPWpGaD
Sirolimus—MTOR—Disease—KL—osteoporosis	2.88e-05	0.000156	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6R—osteoporosis	2.88e-05	0.000156	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ATIC—osteoporosis	2.86e-05	0.000155	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PNP—osteoporosis	2.86e-05	0.000155	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—RAP1A—osteoporosis	2.83e-05	0.000153	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—POMC—osteoporosis	2.82e-05	0.000152	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADCY5—osteoporosis	2.81e-05	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTHFR—osteoporosis	2.8e-05	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—WNT1—osteoporosis	2.79e-05	0.000151	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6R—osteoporosis	2.75e-05	0.000149	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KL—osteoporosis	2.72e-05	0.000147	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SPP1—osteoporosis	2.72e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—osteoporosis	2.72e-05	0.000147	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGA—osteoporosis	2.71e-05	0.000147	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF1—osteoporosis	2.71e-05	0.000147	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.68e-05	0.000145	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—IDH2—osteoporosis	2.67e-05	0.000145	CbGpPWpGaD
Sirolimus—FGF2—Disease—IRS2—osteoporosis	2.66e-05	0.000144	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—osteoporosis	2.54e-05	0.000137	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTHLH—osteoporosis	2.52e-05	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BMP2—osteoporosis	2.52e-05	0.000136	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRS1—osteoporosis	2.52e-05	0.000136	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP27A1—osteoporosis	2.51e-05	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—osteoporosis	2.51e-05	0.000136	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—osteoporosis	2.51e-05	0.000135	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO1—osteoporosis	2.49e-05	0.000135	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGB—osteoporosis	2.47e-05	0.000134	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IRS2—osteoporosis	2.46e-05	0.000133	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AGER—osteoporosis	2.45e-05	0.000133	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PSMA2—osteoporosis	2.45e-05	0.000133	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PSMA5—osteoporosis	2.45e-05	0.000133	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ADCY5—osteoporosis	2.44e-05	0.000132	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ACP5—osteoporosis	2.44e-05	0.000132	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—OXCT1—osteoporosis	2.43e-05	0.000132	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CA2—osteoporosis	2.43e-05	0.000132	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LEP—osteoporosis	2.41e-05	0.00013	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PSMA5—osteoporosis	2.38e-05	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PSMA2—osteoporosis	2.38e-05	0.000129	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MGLL—osteoporosis	2.37e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6R—osteoporosis	2.36e-05	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—osteoporosis	2.35e-05	0.000127	CbGpPWpGaD
Sirolimus—FGF2—Disease—IRS1—osteoporosis	2.32e-05	0.000126	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ESR1—osteoporosis	2.3e-05	0.000124	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO1—osteoporosis	2.28e-05	0.000124	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TPI1—osteoporosis	2.27e-05	0.000123	CbGpPWpGaD
Sirolimus—MTOR—Disease—ADCY5—osteoporosis	2.26e-05	0.000122	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PSMA2—osteoporosis	2.25e-05	0.000122	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PSMA5—osteoporosis	2.25e-05	0.000122	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CALCA—osteoporosis	2.22e-05	0.00012	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6R—osteoporosis	2.18e-05	0.000118	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—POMC—osteoporosis	2.16e-05	0.000117	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IRS1—osteoporosis	2.15e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IRS2—osteoporosis	2.14e-05	0.000116	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—P4HB—osteoporosis	2.14e-05	0.000116	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADCY5—osteoporosis	2.13e-05	0.000115	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GAPDH—osteoporosis	2.1e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Disease—MTHFR—osteoporosis	2.08e-05	0.000112	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—POMC—osteoporosis	2.07e-05	0.000112	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SPP1—osteoporosis	2.06e-05	0.000111	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—osteoporosis	2.05e-05	0.000111	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RAP1A—osteoporosis	2.04e-05	0.00011	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PKM—osteoporosis	2.03e-05	0.00011	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FDPS—osteoporosis	2.03e-05	0.00011	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KL—osteoporosis	2.02e-05	0.000109	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—IDH2—osteoporosis	2.02e-05	0.000109	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6R—osteoporosis	2.02e-05	0.000109	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP19A1—osteoporosis	1.99e-05	0.000108	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1—osteoporosis	1.99e-05	0.000108	CbGpPWpGaD
Sirolimus—MTOR—Disease—IRS2—osteoporosis	1.97e-05	0.000107	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PGLS—osteoporosis	1.93e-05	0.000104	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPD2—osteoporosis	1.93e-05	0.000104	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP27A1—osteoporosis	1.9e-05	0.000103	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—osteoporosis	1.89e-05	0.000102	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IRS1—osteoporosis	1.87e-05	0.000101	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IRS2—osteoporosis	1.86e-05	0.000101	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.86e-05	0.000101	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.86e-05	0.0001	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ACP5—osteoporosis	1.84e-05	9.97e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP19A1—osteoporosis	1.83e-05	9.87e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LEP—osteoporosis	1.82e-05	9.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—osteoporosis	1.81e-05	9.78e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—osteoporosis	1.8e-05	9.72e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PNP—osteoporosis	1.76e-05	9.54e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ATIC—osteoporosis	1.76e-05	9.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6R—osteoporosis	1.75e-05	9.49e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ESR1—osteoporosis	1.74e-05	9.41e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.74e-05	9.4e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.73e-05	9.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IRS1—osteoporosis	1.72e-05	9.32e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TPI1—osteoporosis	1.71e-05	9.27e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—osteoporosis	1.71e-05	9.23e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—osteoporosis	1.7e-05	9.21e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO1—osteoporosis	1.65e-05	8.93e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—osteoporosis	1.63e-05	8.81e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSMA2—osteoporosis	1.63e-05	8.8e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSMA5—osteoporosis	1.63e-05	8.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IRS1—osteoporosis	1.63e-05	8.8e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ADCY5—osteoporosis	1.63e-05	8.79e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—osteoporosis	1.62e-05	8.79e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GPX1—osteoporosis	1.62e-05	8.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6R—osteoporosis	1.62e-05	8.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—P4HB—osteoporosis	1.61e-05	8.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GAPDH—osteoporosis	1.58e-05	8.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADCY5—osteoporosis	1.58e-05	8.55e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—POMC—osteoporosis	1.57e-05	8.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RAP1A—osteoporosis	1.54e-05	8.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SPP1—osteoporosis	1.53e-05	8.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6R—osteoporosis	1.53e-05	8.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1—osteoporosis	1.51e-05	8.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA2—osteoporosis	1.5e-05	8.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—OXCT1—osteoporosis	1.5e-05	8.11e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—osteoporosis	1.49e-05	8.08e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ADCY5—osteoporosis	1.49e-05	8.07e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—osteoporosis	1.49e-05	8.04e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MGLL—osteoporosis	1.46e-05	7.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS2—osteoporosis	1.38e-05	7.48e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—osteoporosis	1.37e-05	7.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEP—osteoporosis	1.35e-05	7.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—osteoporosis	1.34e-05	7.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—osteoporosis	1.33e-05	7.22e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP19A1—osteoporosis	1.32e-05	7.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—osteoporosis	1.29e-05	6.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ESR1—osteoporosis	1.29e-05	6.99e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—osteoporosis	1.29e-05	6.98e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—osteoporosis	1.28e-05	6.94e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO1—osteoporosis	1.25e-05	6.74e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—IDH2—osteoporosis	1.24e-05	6.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSMA2—osteoporosis	1.23e-05	6.64e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSMA5—osteoporosis	1.23e-05	6.64e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—osteoporosis	1.22e-05	6.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS1—osteoporosis	1.21e-05	6.53e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—osteoporosis	1.2e-05	6.47e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—osteoporosis	1.19e-05	6.46e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—osteoporosis	1.19e-05	6.45e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.17e-05	6.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—osteoporosis	1.16e-05	6.29e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ACP5—osteoporosis	1.14e-05	6.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6R—osteoporosis	1.13e-05	6.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1—osteoporosis	1.12e-05	6.05e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—osteoporosis	1.1e-05	5.93e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADCY5—osteoporosis	1.08e-05	5.83e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—osteoporosis	1.07e-05	5.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TPI1—osteoporosis	1.06e-05	5.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—osteoporosis	1.05e-05	5.69e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP19A1—osteoporosis	9.96e-06	5.39e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—P4HB—osteoporosis	9.93e-06	5.37e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—osteoporosis	9.92e-06	5.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GAPDH—osteoporosis	9.75e-06	5.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—osteoporosis	9.72e-06	5.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—osteoporosis	9.6e-06	5.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—osteoporosis	9.57e-06	5.18e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RAP1A—osteoporosis	9.49e-06	5.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—osteoporosis	9.05e-06	4.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—osteoporosis	9.03e-06	4.89e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—osteoporosis	8.98e-06	4.86e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADCY5—osteoporosis	8.14e-06	4.4e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—osteoporosis	8.11e-06	4.39e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—osteoporosis	7.93e-06	4.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—osteoporosis	7.81e-06	4.23e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO1—osteoporosis	7.67e-06	4.15e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSMA5—osteoporosis	7.56e-06	4.09e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSMA2—osteoporosis	7.56e-06	4.09e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—osteoporosis	7.48e-06	4.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—osteoporosis	7.21e-06	3.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—osteoporosis	6.81e-06	3.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—osteoporosis	6.72e-06	3.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—osteoporosis	6.7e-06	3.63e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP19A1—osteoporosis	6.14e-06	3.32e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—osteoporosis	5.98e-06	3.24e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—osteoporosis	5.05e-06	2.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADCY5—osteoporosis	5.01e-06	2.71e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—osteoporosis	5e-06	2.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—osteoporosis	4.61e-06	2.49e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—osteoporosis	3.69e-06	1.99e-05	CbGpPWpGaD
